800px-paracetamol_acetaminophen_500_mg_pills

MHRA recall M&A Pharmachem’s paracetamol due to fungal contamination

pharmafile | June 18, 2019 | News story | Manufacturing and Production Contamination, MHRA, fungal, paracetamol, pharma 

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of M&A Pharmachem’s 500mg paracetamol tablets.

The tablets, which were produced in two separate batches of one thousand each, were found to be contaminated with the fungi Penicillium citrinium and Penicillium brevicompactum.

A number of tablets in each batch were found to be discoloured due to the fungal contamination.

However officials believe that patients have not taken the drugs as the discolouration is noticeable on opening the pack.

Wholesalers and healthcare professionals have been advised to stop supplying the affected batches as a quarantine has been put in place so that any remaining stock can be sent back to the supplier.

Louis Goss

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing …

MHRA approves Mounjaro for diabetes and weight management

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a …

Latest content